Part I: Case series: Acute management of prescription and nonprescription drug overdoses
2024; Wiley; Volume: 7; Issue: 3 Linguagem: Inglês
10.1002/jac5.1931
ISSN2574-9870
AutoresRyan Feldman, James B. Leonard,
Tópico(s)Cardiovascular Syncope and Autonomic Disorders
ResumoJACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACYVolume 7, Issue 3 p. 282-304 PSAP IN JACCP Part I: Case series: Acute management of prescription and nonprescription drug overdoses Ryan Feldman Pharm.D., Ryan Feldman Pharm.D. orcid.org/0000-0002-6630-3288 Search for more papers by this authorJames Leonard Pharm.D., James Leonard Pharm.D. orcid.org/0000-0002-6444-8950 Search for more papers by this author Ryan Feldman Pharm.D., Ryan Feldman Pharm.D. orcid.org/0000-0002-6630-3288 Search for more papers by this authorJames Leonard Pharm.D., James Leonard Pharm.D. orcid.org/0000-0002-6444-8950 Search for more papers by this author First published: 18 March 2024 https://doi.org/10.1002/jac5.1931Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 National Institute of Drug Abuse. Overdose Death Rates [internet database]. 2020. Google Scholar 2Gummin DD, Mowry JB, Beuhler MC, Spyker DA, Bronstein AC, Rivers LJ, et al. 2020 annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 38th annual report. Clin Toxicol (Phila). 2021; 59: 1282–1501. 10.1080/15563650.2021.1989785 PubMedWeb of Science®Google Scholar 3Thompson TM, Theobald J, Lu T, Erickson TB. The general approach to the poisoned patient. Dis Mon. 2014; 60: 509–524. 10.1016/j.disamonth.2014.10.002 PubMedWeb of Science®Google Scholar 4Holstege CP, Borek HA. Toxidromes. Crit Care Clin. 2012; 28: 479–498. 10.1016/j.ccc.2012.07.008 PubMedWeb of Science®Google Scholar 5Benson BE, Hoppu K, Troutman WG, Bedry R, Erdman A, Höjer J, et al. Position paper update: gastric lavage for gastrointestinal decontamination. Clin Toxicol (Phila). 2013; 51: 140–146. 10.3109/15563650.2013.770154 CASPubMedWeb of Science®Google Scholar 6Chyka PA, Seger D, Krenzelok EP, American Academy of clinical toxicology, European Association of Poisons Centres and Clinical Toxicologists, et al. Position paper: single-dose activated charcoal. Clin Toxicol (Phila). 2005; 43: 61–87. 10.1081/CLT-51867 CASPubMedWeb of Science®Google Scholar 7Hoegberg LCG, Shepherd G, Wood DM, Johnson J, Hoffman RS, Caravati EM, et al. Systematic review on the use of activated charcoal for gastrointestinal decontamination following acute oral overdose. Clin Toxicol (Phila). 2021; 59: 1196–1227. 10.1080/15563650.2021.1961144 CASPubMedWeb of Science®Google Scholar 8 American College of Medical Toxicology (ACMT). Guidance document: management priorities in salicylate toxicity. J Med Toxicol. 2015; 11: 149–152. 10.1007/s13181-013-0362-3 PubMedGoogle Scholar 9 American Academy of Clinical Toxicology, European Association of Poisons Centres and Clinical Toxicologists (AACT, EAPCCT). Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. J Toxicol Clin Toxicol. 1999; 37: 731–751. 10.1081/CLT-100102451 PubMedWeb of Science®Google Scholar 10Dorrington CL, Johnson DW, Brant R, Multiple Dose Activated Charcoal Complication Study Group. The frequency of complications associated with the use of multiple-dose activated charcoal. Ann Emerg Med. 2003; 41: 370–377. 10.1067/mem.2003.86 PubMedWeb of Science®Google Scholar 11De Weerdt A, Snoeckx A, Germonpré P, Jorens PG. Rapid-onset adult respiratory distress syndrome after activated charcoal aspiration. A pitch-black tale of a potential to kill. Am J Respir Crit Care Med. 2015; 191: 344–345. 10.1164/rccm.201409-1607IM PubMedWeb of Science®Google Scholar 12Thanacoody R, Caravati EM, Troutman B, Höjer J, Benson B, Hoppu K, et al. Position paper update: whole bowel irrigation for gastrointestinal decontamination of overdose patients. Clin Toxicol (Phila). 2015; 53: 5–12. 10.3109/15563650.2014.989326 PubMedWeb of Science®Google Scholar 13Jha VK, Padmaprakash KV. Extracorporeal treatment in the management of acute poisoning: what an intensivist should know? Indian J Crit Care Med. 2018; 22: 862–869. 10.4103/ijccm.IJCCM_425_18 PubMedWeb of Science®Google Scholar 14Hoppe JM, Holderied A, Schönermarck U, Vielhauer V, Anders HJ, Fischereder M. Drug-induced CYP induction as therapy for tacrolimus intoxication. Clin Nephrol Case Stud. 2022; 10: 42–46. 10.5414/CNCS110744 PubMedGoogle Scholar 15Farkas A, Kostic M, Huang CC, Gummin D. Poison center consultation reduces hospital length of stay. Clin Toxicol (Phila). 2022; 60: 863–868. 10.1080/15563650.2022.2039686 PubMedWeb of Science®Google Scholar 16Cohen H, Hoffman RS, Howland MA. Antidepressant poisoning and treatment: a review and case illustration. J Pharm Pract. 1997; 10: 249–270. 10.1177/089719009701000405 Google Scholar 17Ellison DW, Pentel PR. Clinical features and consequences of seizures due to cyclic antidepressant overdose. Am J Emerg Med. 1989; 7: 5–10. 10.1016/0735-6757(89)90075-2 CASPubMedWeb of Science®Google Scholar 18Liebelt EL, Francis PD, Woolf AD. ECG lead aVR versus QRS interval in predicting seizures and arrhythmias in acute tricyclic antidepressant toxicity. Ann Emerg Med. 1995; 26: 195–201. 10.1016/S0196-0644(95)70151-6 CASPubMedWeb of Science®Google Scholar 19Liebelt EL, Ulrich A, Francis PD, Woolf A. Serial electrocardiogram changes in acute tricyclic antidepressant overdoses. Crit Care Med. 1997; 25: 1721–1726. 10.1097/00003246-199710000-00024 CASPubMedWeb of Science®Google Scholar 20Valento M, Liebelt EL. Cyclic Antidepressants. In: LS Nelson, M Howland, NA Lewin, RS Hoffman, SW Smith, LR Goldfrank, editors. Goldfrank's toxicologic emergencies. 11th ed. New York City, NY:McGraw-Hill; 2019. Google Scholar 21Dawling S, Crome P, Braithwaite R. Effect of delayed administration of activated charcoal on nortriptyline absorption. Eur J Clin Pharmacol. 1978; 14: 445–447. 10.1007/BF00716388 CASPubMedWeb of Science®Google Scholar 22Teba L, Schiebel F, Dedhia HV, Lazzell VA. Beneficial effect of norepinephrine in the treatment of circulatory shock caused by tricyclic antidepressant overdose. Am J Emerg Med. 1988; 6: 566–568. 10.1016/0735-6757(88)90092-7 CASPubMedWeb of Science®Google Scholar 23Tran TP, Panacek EA, Rhee KJ, Foulke GE. Response to dopamine vs norepinephrine in tricyclic antidepressant-induced hypotension. Acad Emerg Med. 1997; 4: 864–868. 10.1111/j.1553-2712.1997.tb03811.x CASPubMedWeb of Science®Google Scholar 24Vernon DD, Banner W Jr, Garrett JS, Dean JM. Efficacy of dopamine and norepinephrine for treatment of hemodynamic compromise in amitriptyline intoxication. Crit Care Med. 1991; 19: 544–549. 10.1097/00003246-199104000-00015 CASPubMedWeb of Science®Google Scholar 25Lavonas EJ, Drennan IR, Gabrielli A, Heffner AC, Hoyte CO, Orkin AM, et al. Part 10: special circumstances of resuscitation: 2015 American Heart Association (AHA) guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015; 132: S501–S518. 10.1161/CIR.0000000000000264 PubMedWeb of Science®Google Scholar 26Bruccoleri R, Burns M. A literature review of the use of sodium bicarbonate for the treatment of QRS widening. J Med Toxicol. 2016; 12: 121–129. 10.1007/s13181-015-0483-y CASPubMedWeb of Science®Google Scholar 27Ramasubbu B, James D, Scurr A, Sandiland EA. Serum alkalinisation is the cornerstone of treatment for amitriptyline poisoning. BMJ Case Rep. 2016; 2016: 10. Google Scholar 28Gosselin S, Hoegberg LC, Hoffman RS, Graudins A, Stork CM, Thomas SHL, et al. Evidence-based recommendations on the use of intravenous lipid emulsion therapy in poisoning. Clin Toxicol (Phila). 2016; 54: 899–923. 10.1080/15563650.2016.1214275 CASPubMedWeb of Science®Google Scholar 29 American College of Medical Toxicology (ACMT). ACMT position statement: interim guidance for the use of lipid resuscitation therapy. J Med Toxicol. 2011; 7(1): 81–82. 10.1007/s13181-010-0125-3 PubMedGoogle Scholar 30Hayes BD, Gosselin S, Calello DP, Nacca N, Rollins CJ, Abourbih D, et al. St. Petersburg, FL: Lipid emulsion workgroup. Systematic review of clinical adverse events reported after acute intravenous lipid emulsion administration. Clin Toxicol (Phila). 2016; 54: 365–404. 10.3109/15563650.2016.1151528 CASPubMedWeb of Science®Google Scholar 31Chen HY, Albertson TE, Olson KR. Treatment of drug-induced seizures. Br J Clin Pharmacol. 2016; 81: 412–419. 10.1111/bcp.12720 CASPubMedWeb of Science®Google Scholar 32Coralic Z, Kapur J, Olson KR, Chamberlain JM, Overbeek D, Silbergleit R. Treatment of toxin-related status epilepticus with levetiracetam, fosphenytoin, or valproate in patients enrolled in the established status epilepticus treatment trial. Ann Emerg Med. 2022; 80: 194–202. 10.1016/j.annemergmed.2022.04.020 PubMedWeb of Science®Google Scholar 33Boley S, Stellpflug S. A comparison of resource utilization in the management of anticholinergic delirium between physostigmine and nonantidote therapy. Ann Pharmacother. 2019; 53: 1026–1032. 10.1177/1060028019846654 CASPubMedWeb of Science®Google Scholar 34Boley S, Olives T, Bangh S, Fahrner S, Cole JB. Physostigmine is superior to non-antidote therapy in the management of antimuscarinic delirium: a prospective study from a regional poison center. Clin Toxicol (Phila). 2019; 57: 50–55. 10.1080/15563650.2018.1485154 CASPubMedWeb of Science®Google Scholar 35Pentel P, Peterson CD. Asystole complicating physostigmine treatment of tricyclic antidepressant overdose. Ann Emerg Med. 1980; 9: 588–590. 10.1016/S0196-0644(80)80232-0 CASPubMedWeb of Science®Google Scholar 36Arens A, Kearney T. Adverse effects of physostigmine. J Med Toxicol. 2019; 15: 184–191. 10.1007/s13181-019-00697-z CASPubMedWeb of Science®Google Scholar 37Arens A, Shah K, Al-Abri S, Olson KR, Kearney T. Safety and effectiveness of physostigmine: a 10-year retrospective review. Clin Toxicol (Phila). 2018; 56: 101–107. 10.1080/15563650.2017.1342828 CASPubMedWeb of Science®Google Scholar 38Kane SP. The Top 300 of 2020, ClinCalc DrugStats Database, Version 202208 [internet database] ClinCalc. wwwclincalccom/DrugStats/Top300Drugsaspx Updated 24 Aug, 2022. Google Scholar 39Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020; 383: 1305–1316. 10.1056/NEJMoa2019422 PubMedWeb of Science®Google Scholar 40Chen X, Yang Z. Successful treatment of propafenone-induced cardiac arrest by calcium gluconate. Am J Emerg Med. 2017; 35: 1209.e1–1209.e2. 10.1016/j.ajem.2017.04.006 PubMedWeb of Science®Google Scholar 41Ovaska H, Ludman A, Spencer EP, Wood DM, Jones AL, Dargan PI. Propafenone poisoning—a case report with plasma propafenone concentrations. J Med Toxicol. 2010; 6: 37–40. 10.1007/s13181-010-0037-2 CASPubMedGoogle Scholar 42Brumfield E, Bernard KRL, Kabrhel C. Life-threatening flecainide overdose treated with intralipid and extracorporeal membrane oxygenation. Am J Emerg Med. 2015; 1840(33): e3–e5. Google Scholar 43Caré W, Larabi IA, Langrand J, Medernach C, Alvarez JC, Vill A. Poisoning associated with inappropriate use of a eutectic mixture of lidocaine and prilocaine before laser-assisted hair removal: about 3 cases. Int J Leg Med. 2019; 133: 843–846. 10.1007/s00414-018-1858-9 PubMedWeb of Science®Google Scholar 44Devin R, Garrett P, Anstey C. Managing cardiovascular collapse in severe flecainide overdose without recourse to extracorporeal therapy. Emerg Med Australas. 2007; 19: 155–159. 10.1111/j.1742-6723.2006.00909.x CASPubMedWeb of Science®Google Scholar 45Bowman N, Seger D. One pill can kill: a literature review of propafenone. Clin Toxicol (Phila). 2017; 55: 761. Web of Science®Google Scholar 46Mostafa AMT, Ershad M, Dela Cruz M, Vearrier D. Fatal flecainide overdose [Abstract]. Clin Toxicol (Phila). 2019; 57: 1002–1003. Web of Science®Google Scholar 47Valentino MA, Panakos A, Ragupathi L, Williams J, Pavri BB. Flecainide toxicity: a case report and systematic review of its electrocardiographic patterns and management. Cardiovasc Toxicol. 2017; 17: 260–266. 10.1007/s12012-016-9380-0 CASPubMedWeb of Science®Google Scholar 48Winecoff AP, Hariman RJ, Grawe JJ, Wang Y, Bauman JL. Reversal of the electrocardiographic effects of cocaine by lidocaine. Part 1. Comparison with sodium bicarbonate and quinidine. Pharmacother J Hum Pharmacol Drug Ther. 1994; 14: 698–703. 10.1002/j.1875-9114.1994.tb04162.x CASPubMedWeb of Science®Google Scholar 49Wynn J, Fingerhood M, Keefe D, Maza S, Miura D, Somberg JC. Refractory ventricular tachycardia with flecainide. Am Heart J. 1986; 112: 174–175. 10.1016/0002-8703(86)90699-X CASPubMedWeb of Science®Google Scholar 50Reynolds JC, Judge BS. Successful treatment of flecainide-induced cardiac arrest extracorporeal membrane oxygenation in the ED. Am J Emerg Med. 2015; 33(1542): e1–e2. PubMedGoogle Scholar 51Pavlidakey PG, Brodell EE, Helms SE. Diphenhydramine as an alternative local anesthetic agent. J Clin Aesthet Dermatol. 2009; 2: 37–40. PubMedGoogle Scholar 52Hughes AR, Lin A, Hendrickson RG, Toxicology Investigators Consortium (ToxIC). Clinical and patient characteristics associated with severe outcome in diphenhydramine toxicity. Clin Toxicol (Phila). 2021; 59: 918–925. 10.1080/15563650.2021.1891244 CASPubMedWeb of Science®Google Scholar 53Radovanovic D, Meier PJ, Guirguis M, Lorent JP, Kupferschmidt H. Dose-dependent toxicity of diphenhydramine overdose. Hum Exp Toxicol. 2000; 19: 489–495. 10.1191/096032700671040438 CASPubMedWeb of Science®Google Scholar 54Panchal AR, Bartos JA, Cabanas JG, Donnino MW, Drennan IR, Hirsch KG, et al. Part 3: adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2020; 142: S366–S468. 10.1161/CIR.0000000000000916 PubMedWeb of Science®Google Scholar 55Clemons J, Jandu A, Stein B, Chary M. Efficacy of lipid emulsion therapy in treating cardiotoxicity from diphenhydramine ingestion: a review and analysis of case reports. Clin Toxicol (Phila). 2022; 60: 550–558. 10.1080/15563650.2022.2038187 CASPubMedWeb of Science®Google Scholar 56Burns MJ, Linden CH, Graudins A, Brown RM, Fletcher KE. A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning. Ann Emerg Med. 2000; 35: 374–381. 10.1016/S0196-0644(00)70057-6 CASPubMedWeb of Science®Google Scholar 57Van Kernebeek MW, Ghesquiere M, Vanderbruggen N, Verhoeven E, Hubloue I, Crunelle CL. Rivastigmine for the treatment of anticholinergic delirium following severe procyclidine intoxication. Clin Toxicol (Phila). 2021; 59: 447–448. 10.1080/15563650.2020.1818768 CASPubMedWeb of Science®Google Scholar 58McCabe DJ, McGillis E, Willenbring BA. Clinical effects of intravenous bupropion misuse reported to a regional poison center. Am J Emerg Med. 2021; 47: 86–89. 10.1016/j.ajem.2021.03.061 PubMedWeb of Science®Google Scholar 59McCabe DJ, McGillis E, Willenbring BA. The timing of clinical effects of bupropion misuse via insufflation reported to a regional poison center. J Emerg Med. 2022; 62: 175–181. 10.1016/j.jemermed.2021.07.052 PubMedWeb of Science®Google Scholar 60Casey ER, Scott MG, Tang S, Mullins ME. Frequency of false positive amphetamine screens due to bupropion using the Syva EMIT II immunoassay. J Med Toxicol. 2011; 7: 105–108. 10.1007/s13181-010-0131-5 PubMedGoogle Scholar 61Caillier B, Pilote S, Castonguay A, Patoine D, Ménard-Desrosiers V, Vigneault P, et al. QRS widening and QT prolongation under bupropion: a unique cardiac electrophysiological profile. Fundam Clin Pharmacol. 2012; 26: 599–608. 10.1111/j.1472-8206.2011.00953.x CASPubMedWeb of Science®Google Scholar 62Shepherd G, Velez LI, Keyes DC. Intentional bupropion overdoses. J Emerg Med. 2004; 27: 147–151. 10.1016/j.jemermed.2004.02.017 PubMedWeb of Science®Google Scholar 63Spiller HA, Ramoska EA, Krenzelok EP, Sheen SR, Borys DJ, Villalobos D, et al. Bupropion overdose: a 3-year multi-center retrospective analysis. Am J Emerg Med. 1994; 12: 43–45. 10.1016/0735-6757(94)90195-3 CASPubMedWeb of Science®Google Scholar 64Starr P, Klein-Schwartz W, Spiller H, Kern P, Ekleberry SE, Kunkel S. Incidence and onset of delayed seizures after overdoses of extended-release bupropion. Am J Emerg Med. 2009; 27: 911–915. 10.1016/j.ajem.2008.07.004 PubMedWeb of Science®Google Scholar 65Stranges D, Lucerna A, Espinosa J, Malik N, Mongeau M, Schiers K, et al. A Lazarus effect: a case report of bupropion overdose mimicking brain death. World J Emerg Med. 2018; 9: 67–69. 10.5847/wjem.j.1920-8642.2018.01.011 PubMedWeb of Science®Google Scholar 66Heise CW, Skolnik AB, Raschke RA, Owen-Reece H, Graeme KA. Two cases of refractory cardiogenic shock secondary to bupropion successfully treated with veno-arterial extracorporeal membrane oxygenation. J Med Toxicol. 2016; 12: 301–304. 10.1007/s13181-016-0539-7 CASPubMedGoogle Scholar 67Druteika D, Zed PJ. Cardiotoxicity following bupropion overdose. Ann Pharmacother. 2002; 36: 1791–1795. 10.1345/aph.1C045 CASPubMedWeb of Science®Google Scholar 68Franco V. Wide complex tachycardia after bupropion overdose. Am J Emerg Med. 2015; 33(1540): e3–e5. Google Scholar 69Richards JR, Albertson TE, Derlet RW, Lange RA, Olson KR, Horowitz BZ. Treatment of toxicity from amphetamines, related derivatives, and analogues: a systematic clinical review. Drug Alcohol Depend. 2015; 150: 1–13. 10.1016/j.drugalcdep.2015.01.040 CASPubMedWeb of Science®Google Scholar 70Lange RA, Cigarroa RG, Flores ED, McBride W, Kim AS, Wells PJ, et al. Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade. Ann Intern Med. 1990; 15(112): 897–903. 10.7326/0003-4819-112-12-897 Google Scholar 71Wills BK, Zell-Kanter M, Aks SE. Bupropion-associated QRS prolongation unresponsive to sodium bicarbonate therapy. Am J Ther. 2009; 16: 193–196. 10.1097/MJT.0b013e3180a5bd83 PubMedWeb of Science®Google Scholar 72Bauman JL, Didomenico RJ, Galanter WL. Mechanisms, manifestations, and management of digoxin toxicity in the modern era. Am J Cardiovasc Drugs. 2006; 6: 77–86. 10.2165/00129784-200606020-00002 CASPubMedGoogle Scholar 73Wofford JL, Ettinger WH. Risk factors and manifestations of digoxin toxicity in the elderly. Am J Emerg Med. 1991; 9: 11–15. 10.1016/0735-6757(91)90161-C CASPubMedWeb of Science®Google Scholar 74Weintraub M. Interpretation of the serum digoxin concentration. Clin Pharmacokinet. 1977; 2: 205–219. 10.2165/00003088-197702030-00005 CASPubMedWeb of Science®Google Scholar 75Beller GA, Smith TW, Abelmann WH, Haber E, Hood WB Jr. Digitalis intoxication. A prospective clinical study with serum level correlations. N Engl J Med. 1971; 284: 989–997. 10.1056/NEJM197105062841801 CASPubMedWeb of Science®Google Scholar 76Levine M, Nikkanen H, Pallin DJ. The effects of intravenous calcium in patients with digoxin toxicity. J Emerg Med. 2011; 40: 41–46. 10.1016/j.jemermed.2008.09.027 PubMedWeb of Science®Google Scholar 77Chan BS, Isbister GK, Chiew A, Isoardi K, Buckley NA. Clinical experience with titrating doses of digoxin antibodies in acute digoxin poisoning (ATOM-6). Clin Toxicol (Phila). 2022; 60: 433–439. 10.1080/15563650.2021.1968422 CASPubMedWeb of Science®Google Scholar 78Chan BS, Isbister GK, O'Leary M, Chiew A, Buckley NA. Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1). Clin Toxicol (Phila). 2016; 54: 488–494. 10.1080/15563650.2016.1175620 CASPubMedWeb of Science®Google Scholar 79Hickey AR, Wenger TL, Carpenter VP, Tilson HH, Hlatky MA, Furberg CD, et al. Digoxin immune fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study. J Am Coll Cardiol. 1991; 17: 590–598. 10.1016/S0735-1097(10)80170-6 CASPubMedWeb of Science®Google Scholar 80Chan BS, Buckley NA. Digoxin-specific antibody fragments in the treatment of digoxin toxicity. Clin Toxicol (Phila). 2014; 52: 824–836. 10.3109/15563650.2014.943907 CASPubMedWeb of Science®Google Scholar 81Hassan SA, Goyal A. Digoxin immune Fab. StatPearls [Internet]. StatPearls Publishing; 2022. Google Scholar 82Mycyk MB, Bryant SM, Cumpston KL. Late rebound digoxin toxicity after digoxin-specific antibody fab fragments therapy in anuric patient. J Emerg Med. 2003; 24: 91. PubMedGoogle Scholar 83Ujhelyi MR, Robert S, Cummings DM, Colucci RD, Green PJ, Sailstad J, et al. Influence of digoxin immune Fab therapy and renal dysfunction on the disposition of total and free digoxin. Ann Intern Med. 1993; 119: 273–277. 10.7326/0003-4819-119-4-199308150-00004 CASPubMedWeb of Science®Google Scholar 84Zdunek M, Mitra A, Mokrzycki MH. Plasma exchange for the removal of digoxin-specific antibody fragments in renal failure: timing is important for maximizing clearance. Am J Kidney Dis. 2000; 36: 177–183. 10.1053/ajkd.2000.8291 CASPubMedWeb of Science®Google Scholar 85Delicata L, Gatt A, Paris JL, Bonello J. Symptomatic digoxin toxicity in a patient on haemodialysis. BMJ Case Rep. 2020; 13(6):e234899. 10.1136/bcr-2020-234899 PubMedGoogle Scholar 86Lung DD, Olson KR. Hypoglycemia in pediatric sulfonylurea poisoning: an 8-year poison center retrospective study. Pediatrics. 2011; 127: e1558–e1564. 10.1542/peds.2010-3235 PubMedWeb of Science®Google Scholar 87Klein-Schwartz W, Stassinos GL, Isbister GK. Treatment of sulfonylurea and insulin overdose. Br J Clin Pharmacol. 2016; 81: 496–504. 10.1111/bcp.12822 CASPubMedWeb of Science®Google Scholar 88Alexander RS, Canver BR, Sue KL, Morford KL. Xylazine and overdoses: trends, concerns, and recommendations. Am J Public Health. 2022; 112: 1212–1216. 10.2105/AJPH.2022.306881 PubMedWeb of Science®Google Scholar 89Gugelmann MG, DeRoos JF. Miscellaneous antihypertensives and pharmacologically related agents. In: LS Nelson, M Howland, NA Lewin, et al., editors. Goldfrank's Toxicologic emergencies. 11th ed. New York City, NY: McGraw-Hill; 2019. Google Scholar 90Toce MS, Freiman E, O'Donnell KA, Burns MM. Clinical effects of pediatric clonidine exposure: a retrospective cohort study at a single tertiary care center. J Emerg Med. 2021; 60: 58–66. 10.1016/j.jemermed.2020.09.018 PubMedWeb of Science®Google Scholar 91Perruchoud C, Bovy M, Durrer A, Rosato M, Rutschmann B, Mustaki JP, et al. Severe hypertension following accidental clonidine overdose during the refilling of an implanted intrathecal drug delivery system. Neuromodulation. 2012; 15: 31–34. 10.1111/j.1525-1403.2011.00392.x CASPubMedWeb of Science®Google Scholar 92Farsang C, Kunos G. Naloxone reverses the antihypertensive effect of clonidine. Br J Pharmacol. 1979; 67: 161–164. 10.1111/j.1476-5381.1979.tb08661.x CASPubMedWeb of Science®Google Scholar 93Seger DL, Loden JK. Naloxone reversal of clonidine toxicity: dose, dose, dose. Clin Toxicol (Phila). 2018; 56: 873–879. 10.1080/15563650.2018.1450986 CASPubMedWeb of Science®Google Scholar 94Halil H, Tuygun N, Polat E, Karacan CD. Minimum ingested iron cut-off triggering serious iron toxicity in children. Pediatr Int. 2019; 61: 444–448. 10.1111/ped.13834 CASPubMedWeb of Science®Google Scholar 95Bateman DN, Eagling V, Sandilands EA, Jackson G, Crawford C, Hawkins L, et al. Iron overdose epidemiology, clinical features and iron concentration-effect relationships: the UK experience 2008-2017. Clin Toxicol (Phila). 2018; 56: 1098–1106. 10.1080/15563650.2018.1455978 CASPubMedWeb of Science®Google Scholar 96Perrone JM. Iron. In: LS Nelson, M Howland, NA Lewin, Hoffman RS, Smith SW, Goldfrank LR, editors. Goldfrank's Toxicologic emergencies. 11th ed. New York City, NY: McGraw-Hill; 2019 https://accesspharmacy.mhmedical.com/content.aspx?bookid=2569§ionid=210271950 Google Scholar 97Howland M. Deferoxamine. In: LS Nelson, M Howland, NA Lewin, Hoffman RS, Smith SW, Golfrank LR, editors. Goldfrank's toxicologic emergencies. 11th ed. New York City, NY: McGraw-Hill; 2019. Google Scholar 98Wright SW, Valento M, Mazor SS, Chen BC. Severe iron poisoning treated with prolonged deferoxamine infusion: a case report. Toxicol Commun. 2018; 2(1): 6–9. 10.1080/24734306.2018.1425280 Google Scholar 99Robins-Browne RM, Prpic JK. Effects of iron and desferrioxamine on infections with Yersinia enterocolitica. Infect Immun. 1985; 47: 774–779. 10.1128/iai.47.3.774-779.1985 CASPubMedWeb of Science®Google Scholar 100Manoguerra AS, Erdman AR, Woolf AD, Chyka PA, Caravati EM, Scharman EJ, et al. Valproic acid poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol. 2008; 46: 661–676. 10.1080/15563650802178136 CASPubMedWeb of Science®Google Scholar 101Spiller HA, Krenzelok EP, Klein-Schwartz W, Winter ML, Weber JA, Sollee DR, et al. Multicenter case series of valproic acid ingestion: serum concentrations and toxicity. Clin Toxicol. 2000; 38: 755–760. 10.1081/CLT-100102388 CASPubMedWeb of Science®Google Scholar 102Bohan TP, Helton E, McDonald I, König S, Gazitt S, Sugimoto T, et al. Effect of l-carnitine treatment for valproate-induced hepatotoxicity. Neurology. 2001; 56: 1405–1409. 10.1212/WNL.56.10.1405 CASPubMedWeb of Science®Google Scholar 103Tincu RC, Cobilinschi C, Tomescu D, Coman L, Tincu I, Diaconu C, et al. Favourable results for L-carnitine use in valproic acid acute poisoning. Farmacia. 2017; 65: 396–400. CASWeb of Science®Google Scholar 104Doyon S. Antiepileptics. In: LS Nelson, M Howland, NA Lewin, Hoffman RS, Smith SW, Goldfrank LR, editors. Goldfrank's toxicologic emergencies. 11th ed. New York City, NY: McGraw-Hill; 2019. p. 719–731. Google Scholar 105Park MK, Lim KS, Kim TE, Han HK, Yi SJ, Shin KH, et al. Reduced valproic acid serum concentrations due to drug interactions with carbapenem antibiotics: overview of 6 cases. Ther Drug Monit. 2012; 34: 599–603. 10.1097/FTD.0b013e318260f7b3 CASPubMedWeb of Science®Google Scholar 106Khobrani MA, Dudley SW, Huckleberry YC, Kopp BJ, Biggs AD, French RNE, et al. Intentional use of carbapenem antibiotics for valproic acid toxicity: a case report. J Clin Pharm Ther. 2018; 43: 723–725. 10.1111/jcpt.12705 CASPubMedWeb of Science®Google Scholar 107Ghannoum M, Laliberté M, Nolin TD, MacTier R, Lavergne V, Hoffman RS, et al. Extracorporeal treatment for valproic acid poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol (Phila). 2018; 53: 454–465. 10.3109/15563650.2015.1035441 Google Scholar 108Chyka PA, Erdman AR, Christianson G, Wax PM, Booze LL, Manoguerra AS, et al. Salicylate poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol. 2007; 45: 95–131. 10.1080/15563650600907140 CASPubMedWeb of Science®Google Scholar 109Rivera W, Kleinschmidt KC, Velez LI, Shepherd G, Keyes DC. Delayed salicylate toxicity at 35 hours without early manifestations following a single salicylate ingestion. Ann Pharmacother. 2004; 38: 1186–1188. 10.1345/aph.1D575 PubMedWeb of Science®Google Scholar 110Moss MJ, Fisher JA, Kenny TA, Palmer AC, Thompson JA, Wolfer H, et al. Salicylate toxicity after undetectable serum salicylate concentration: a retrospective cohort study. Clin Toxicol. 2019; 57: 137–140. 10.1080/15563650.2018.1502442 CASPubMedWeb of Science®Google Scholar 111Kashani KB, Steuernagle Iv JH, Qian Q. Spurious hyperchloremia in the presence of elevated plasma salicylate: a cohort study. Nephron. 2018; 138: 186–191. 10.1159/000484636 CASPubMedWeb of Science®Google Scholar 112Palmer BF, Clegg DJ. Salicylate toxicity. N Engl J Med. 2020; 382: 2544–2555. 10.1056/NEJMra2010852 PubMedWeb of Science®Google Scholar 113Juurlink DN, Gosselin S, Kielstein JT, Ghannoum M, Lavergne V, Nolin TD, et al. Extracorporeal treatment for salicylate poisoning: systematic review and recommendations from the EXTRIP workgroup. Ann Emerg Med. 2015; 66: 165–181. 10.1016/j.annemergmed.2015.03.031 PubMedWeb of Science®Google Scholar 114Stolbach AI, Hoffman RS, Nelson LS. Mechanical ventilation was associated with acidemia in a case series of salicylate-poisoned patients. Acad Emerg Med. 2008; 15: 866–869. 10.1111/j.1553-2712.2008.00205.x PubMedWeb of Science®Google Scholar 115McCabe DJ, Lu JJ. The association of hemodialysis and survival in intubated salicylate-poisoned patients. Am J Emerg Med. 2017; 35: 899–903. 10.1016/j.ajem.2017.04.017 PubMedWeb of Science®Google Scholar Volume7, Issue3March 2024Pages 282-304 ReferencesRelatedInformation
Referência(s)